Related Experiment Videos
Immunologic aspects of unknown primary melanoma
Surgery
|January 1, 1980
Summary
Immune responses in patients with unknown primary melanoma are comparable to those with known primary melanoma. Studies found no significant differences in cellular or humoral immunity between the two groups.
Area of Science:
- Immunology
- Oncology
- Dermatology
Background:
- Melanoma of unknown primary (MUP) presents a diagnostic challenge.
- Understanding immune responses in MUP is crucial for prognosis and treatment.
Purpose of the Study:
- To compare cellular and humoral immune responses between patients with stage II unknown primary melanoma and stage II known primary melanoma.
- To identify potential immune system differences that could inform MUP management.
Main Methods:
- Comparison of delayed cutaneous hypersensitivity (DNCB reactivity) between groups.
- Assessment of antibodies to cultured melanoma cells in patient sera.
- Evaluation of lymphoproliferative assays (Concanavalin A, mixed leukocyte culture, unstimulated lymphocyte blastogenesis).
Main Results:
- Delayed cutaneous hypersensitivity to DNCB was similar in both unknown and known primary melanoma groups.
- Antibody prevalence to melanoma cells was slightly higher in unknown primary patients, but titers did not differ significantly.
- Lymphoproliferative assays showed no significant differences in lymphocyte reactivity between the two patient groups.
Conclusions:
- No detectable differences in humoral or cellular immune responses were found between stage II unknown primary melanoma patients and stage II known primary melanoma patients with similar clinical characteristics.
- Immune profiles appear consistent across these melanoma subgroups, suggesting similar underlying immune system interactions.